Kishan Amar U, Cameron Robert B, Wang Pin-Chieh, Alexander Sherri, Qi Sharon X, Low Daniel A, Kupelian Patrick A, Steinberg Michael L, Lee Jay M, Selch Michael T, Lee Percy
Department of Radiation Oncology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Division of Thoracic Surgery, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California.
Pract Radiat Oncol. 2015 Nov-Dec;5(6):366-73. doi: 10.1016/j.prro.2015.07.010. Epub 2015 Aug 1.
The purpose of the study was to determine whether intensity modulated radiation therapy delivered via helical tomotherapy improves local control (LC) after pleurectomy/decortication (P/D) for malignant pleural mesothelioma compared with 3-dimensional conformal radiation therapy (3D-CRT).
Forty-five consecutive patients were treated with adjuvant radiation to 45 Gy in 1.8 Gy fractions after P/D between 2006 and 2014; 23 received 3D-CRT, and 22 received tomotherapy. Kaplan-Meier analysis was used to calculate overall survival, time to in-field or local failure (LF), and time to out-of-field failure. The Student t test and Fisher exact test were used to detect between-group differences.
Median follow-up time was 19.4 months and 12.7 months for the 3D-CRT and tomotherapy groups, respectively. Eighty-two percent of patients had T3/T4 disease, and 64% had positive nodes; 17.4% and 41% of patients in the 3D-CRT and tomotherapy groups had nonepithelioid histology, respectively. Mean planning target volume dose, percentage of planning target volume receiving 100% of the prescription dose, and lung doses were significantly greater with tomotherapy (P < .05), but toxicity rates (including radiation pneumonitis rates) were equivalent. LC was significantly improved with tomotherapy on Kaplan-Meier analysis with outcomes censored at 2 years (P < .05); uncensored, this became a trend (P = .06). Median time to LF was 19 months with tomotherapy and 10.9 months in 3D-CRT (the latter interval being less than the median follow-up in the tomotherapy group). On univariate analysis, treatment modality was the only significant predictor of LC (P < .05). Isolated LF was significantly more frequent with 3D-CRT (P < .05). Conversely, isolated out-of-field failure was significantly more frequent with tomotherapy (P < .05). Overall survival and out-of-field control were not significantly different.
Tomotherapy after P/D for malignant pleural mesothelioma is associated with improved target coverage that translates into improved LC compared with 3D-CRT. This is related to a change in failure patterns, with isolated LF being more common in the 3D-CRT group and isolated out-of-field failures predominating in the tomotherapy group.
本研究旨在确定与三维适形放射治疗(3D-CRT)相比,通过螺旋断层放射治疗进行的调强放射治疗是否能改善恶性胸膜间皮瘤胸膜切除术/胸膜剥脱术(P/D)后的局部控制(LC)。
2006年至2014年间,45例连续患者在P/D后接受辅助放疗,剂量为45 Gy,每次分割剂量1.8 Gy;23例接受3D-CRT,22例接受断层放射治疗。采用Kaplan-Meier分析计算总生存期、野内或局部失败时间(LF)以及野外失败时间。使用学生t检验和Fisher精确检验检测组间差异。
3D-CRT组和断层放射治疗组的中位随访时间分别为19.4个月和12.7个月。82%的患者患有T3/T4期疾病,64%的患者有阳性淋巴结;3D-CRT组和断层放射治疗组分别有17.4%和41%的患者为非上皮样组织学类型。断层放射治疗的平均计划靶体积剂量、接受100%处方剂量的计划靶体积百分比和肺剂量显著更高(P < .05),但毒性发生率(包括放射性肺炎发生率)相当。在2年时进行结果删失的Kaplan-Meier分析中,断层放射治疗显著改善了LC(P < .05);未删失时,这成为一种趋势(P = .06)。断层放射治疗的中位LF时间为19个月,3D-CRT为10.9个月(后者的时间间隔小于断层放射治疗组的中位随访时间)。单因素分析中,治疗方式是LC的唯一显著预测因素(P < .05)。3D-CRT的孤立LF明显更常见(P < .05)。相反,断层放射治疗的孤立野外失败明显更常见(P < .05)。总生存期和野外控制无显著差异。
与3D-CRT相比,恶性胸膜间皮瘤P/D后的断层放射治疗与改善的靶区覆盖相关,这转化为更好的LC。这与失败模式的改变有关,3D-CRT组中孤立LF更常见,而断层放射治疗组中孤立野外失败占主导。